Physician profile
Lori M Smith
NPI 1346283751
$2,036.48
in general payments reported to CMS, 2019-2025
30 companies · $30.07 in 2025
The $30.07 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $641 · 2020: $211 · 2021: $438 · 2022: $613 · 2023: $62.04 · 2024: $42.61 · 2025: $30.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $134.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $383.93 | 2019-2022 | |
| Abbvie INC. | $161.24 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $151.01 | 2022 | |
| Allergan, INC. | $135.88 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.89 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $126.07 | 2019-2021 | |
| Lilly USA, LLC | $125.33 | 2019-2021 | |
| Amgen INC. | $114.86 | 2019-2022 | |
| Gilead Sciences, INC. | $89.08 | 2023-2024 | Veklury |
| Astrazeneca Pharmaceuticals LP | $56.30 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $56.16 | 2019 | |
| Pfizer INC. | $54.78 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $47.12 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.35 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $43.24 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $42.17 | 2020-2021 | |
| Ucb, INC. | $38.75 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.76 | 2022 | |
| Amneal Pharmaceuticals LLC | $25.40 | 2019 | |
| Apria Healthcare LLC | $25.23 | 2021 | |
| Glaxosmithkline, LLC. | $23.61 | 2019 | |
| Amarin Pharma, INC. | $18.93 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.30 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.07 | 2019 | |
| Grifols USA, LLC | $17.19 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.81 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.93 | 2022 | |
| Merck Sharp & Dohme LLC | $11.93 | 2020 | |
| Sanofi Pasteur INC. | $11.76 | 2019 | |
| Genentech USA, INC. | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.